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INTRODUCTION {#cncr30790-sec-0005}
============

Colorectal cancer (CRC) is the second most common and lethal malignancy among Hispanic/Latino individuals (henceforth referred to as Latinos), who are the fastest growing minority in the United States.[1](#cncr30790-bib-0001){ref-type="ref"}, [2](#cncr30790-bib-0002){ref-type="ref"} Compared with non‐Hispanic white (NHW) individuals, Latino patients present with CRC at an earlier age, are 20% to 40% more likely to present with advanced disease, and have a 20% to 30% increased stage‐specific mortality.[2](#cncr30790-bib-0002){ref-type="ref"}, [3](#cncr30790-bib-0003){ref-type="ref"}, [4](#cncr30790-bib-0004){ref-type="ref"}, [5](#cncr30790-bib-0005){ref-type="ref"}, [6](#cncr30790-bib-0006){ref-type="ref"}, [7](#cncr30790-bib-0007){ref-type="ref"}, [8](#cncr30790-bib-0008){ref-type="ref"} To the best of our knowledge, the reasons for such disparities are incompletely understood and may partly reflect different biology, treatment, and surveillance patterns.[9](#cncr30790-bib-0009){ref-type="ref"}, [10](#cncr30790-bib-0010){ref-type="ref"}

Genomic instability results from a loss of DNA mismatch repair (MMR) activity. Approximately 10% to 15% of CRC tumors are associated with microsatellite instability (MSI),[11](#cncr30790-bib-0011){ref-type="ref"}, [12](#cncr30790-bib-0012){ref-type="ref"} whereby short repetitive DNA sequences undergo an increase or decrease in repeat length. Mechanistically, somatic events, such as MutL homolog 1 (*MLH1*) promoter hypermethylation, account for the majority of MSI‐H cancers, with a smaller percentage attributable to germline mutations in a DNA MMR gene (*MLH1*; MutS homolog 2 \[*MSH2*\]; MutS homolog 6 \[*MSH6*\]; or PMS1 homolog 2, mismatch repair system component \[*PMS2*\]).[13](#cncr30790-bib-0013){ref-type="ref"}, [14](#cncr30790-bib-0014){ref-type="ref"} Individuals with germline MMR mutations are classified as having Lynch syndrome,[15](#cncr30790-bib-0015){ref-type="ref"}, [16](#cncr30790-bib-0016){ref-type="ref"} which is the most common inherited form of CRC, accounting for 3% to 6% of cases.[17](#cncr30790-bib-0017){ref-type="ref"}, [18](#cncr30790-bib-0018){ref-type="ref"}, [19](#cncr30790-bib-0019){ref-type="ref"}

Two recent studies examined potential differences in MSI by ethnicity/race and reported no significant differences.[20](#cncr30790-bib-0020){ref-type="ref"}, [21](#cncr30790-bib-0021){ref-type="ref"} Both studies estimated the rate of MMR‐deficient (dMMR) tumors in Latino individuals to be approximately 12%.[20](#cncr30790-bib-0020){ref-type="ref"}, [21](#cncr30790-bib-0021){ref-type="ref"} Another study by De Jesus‐Monge et al found different results, reporting a rate of 4.3% for high MSI tumors in a cohort of 164 Puerto Rican patients with CRC.[22](#cncr30790-bib-0022){ref-type="ref"} However, all these studies were limited by sample size and the lack of germline testing performed. A better understanding of tumor characteristics and the extent of CRC heterogeneity in Latino patients may help explain outcome disparities as well as inform screening and therapeutic decisions in this understudied population.

In the current study, we sought to better characterize the spectrum and prevalence of hereditary syndromes among patients enrolled in the ongoing Hispanic Colorectal Cancer Study (HCCS).

MATERIALS AND METHODS {#cncr30790-sec-0006}
=====================

Study Design and Population {#cncr30790-sec-0007}
---------------------------

The HCCS is a population‐based study of self‐identified Hispanic or Latino individuals with a diagnosis of CRC. Patients are identified through the California Cancer Registry or directly from local hospitals in the Los Angeles region. As of December 2015, a total of 1112 subjects have been enrolled into the HCCS. Men and women with an initial diagnosis of CRC (*International Classification of Diseases for Oncology, 3rd Edition* \[ICD‐O‐3\] codes C18‐C21) after January 1, 2008 were eligible for participation. The current study includes all patients recruited at 2 centers that are part of the HCCS and that report to the California Cancer Registry: the Los Angeles County (LAC) plus University of Southern California (USC) Medical Center (LAC) and USC Norris Comprehensive Cancer Center (Norris); hereafter, these patients will be referred to collectively as the USC subset (265 patients). All participants provided written informed consent. This protocol was approved by the USC Institutional Review Board and the California Institute for the Protection of Human Subjects.

Risk Factor Questionnaires {#cncr30790-sec-0008}
--------------------------

All participants completed a telephone‐based or face‐to‐face interview after study enrollment that included the collection of demographic information (age, sex, and country of birth) and lifestyle exposures during the 2 years before the diagnosis of CRC. Data were collected regarding personal and family histories of CRC, colon polyps, and other cancers. Medical diagnoses of diabetes, Crohn disease, ulcerative colitis, and familial adenomatous polyposis were self‐reported by patients and confirmed by review of the medical records when possible. Body mass index (BMI) was calculated as the individual\'s weight (in kg) 2 years before study recruitment divided by adult height in meters squared (m^2^). Several lifestyle risk factors were queried, including medication use, reproductive history, hormonal contraceptive use, physical activity, body height and weight, alcohol intake, and tobacco use. Ever‐use (yes vs no) of nonsteroidal anti‐inflammatory drugs was defined as use at least 2 times per week for \>1 month during a participant\'s lifetime. Alcohol use was defined as the consumption of any alcoholic beverage (beer, wine, hard cider, sake, liquor, mixed drinks, or cocktails) at least once a week for ≥6 months during the most recent decade of life at the time of enrollment. Being an ever‐smoker was defined as ever smoking at least 1 cigarette per day for ≥3 months. Pack‐years of smoking were calculated based on the number of cigarettes smoked per day and the number of years smoked. An individual was considered to be physically active (yes vs no) if they reported \>20 metabolic equivalent (MET) hours per week of physical activity during the most recent decade of life at the time of enrollment.

Clinical Chart Abstraction {#cncr30790-sec-0009}
--------------------------

A systematic review of each participant\'s medical record was performed at LAC and Norris. Information regarding the following tumor characteristics was retrieved: clinical stage of disease (AJCC 7th Ed., stage I‐IV); primary tumor location (rectal, distal, or proximal); MSI status (stable vs instable); *KRAS* exon 2/3 mutation status (mutant vs wild‐type); *BRAF* ^V600E^ mutation status (mutant vs wild‐type); and immunohistochemical (IHC) staining of the MMR protein products for hMLH1, hMSH2, hMSH6, and hPMS2 (absent vs present). These tumor studies were performed under standard clinical protocols at each facility. Records also were requested from diagnostic hospitals for those individuals with incomplete records regarding these tumor characteristics at LAC or Norris (32 patients; 12%). Not all patients were tested for MMR deficiency and/or MSI as part of routine clinical practice.

Results were reviewed for any participants who had germline genetic analyses performed under standard clinical protocols at Clinical Laboratory Improvement Amendments (CLIA)‐certified laboratories. The specific genetic test performed was indicated based on personal and family history and IHC results after a clinical cancer genetics evaluation. Participants either had genetic testing of ≥1 CRC risk genes (*MLH1*, *MSH2*, *MSH6*, *PMS2*, *MUTYH*, or adenomatous polyposis coli \[*APC*\]) or were tested using a broader multigene panel of 25 genes (*APC*, *ATM*, *BARD1*, bone morphogenetic protein receptor type 1A \[*BMPR1A*\], *BRCA1*, *BRCA2*, *BRIP1*, cadherin 1 \[*CDH1*\], *CDK4*, *CDKN2A* \[*p16INK4a* and *p14ARF*\], *CHEK2*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NBN*, *PALB2*, *PMS2*, phosphatase and tensin homolog \[*PTEN*\], *RAD51C*, *RAD51D*, SMAD family member 4 \[*SMAD4*\], serine/threonine kinase 11 \[*STK11*\], and tumor protein P53 \[*TP53*\]).

Medical records were reviewed and treatment records were abstracted, including neoadjuvant and adjuvant chemotherapy and radiotherapy, as well as all therapies received in the metastatic setting. The date of the initial diagnosis and date of death (if available) or last follow‐up also were recorded.

Family History {#cncr30790-sec-0010}
--------------

Data regarding family history of cancer were gathered from participant questionnaires and genetic counseling clinical notes. Having a first‐degree and/or second‐degree relative with CRC was recorded. If participants reported any family history of cancer, the details were reviewed to determine whether their history fulfilled Amsterdam I or II (AM‐I, AM‐II) clinical criteria for Lynch syndrome. AM‐I participants were those from families with ≥3 relatives with CRC, with 1 being a first‐degree relative of another, in 2 successive generations, and with at least 1 relative diagnosed at age \<50 years.[23](#cncr30790-bib-0023){ref-type="ref"} AM‐II uses the same 3‐2‐1 criteria, but allows for the inclusion of other Lynch syndrome‐associated cancers of the endometrium, small intestine, ureter, or renal pelvis, in addition to CRC.[24](#cncr30790-bib-0024){ref-type="ref"} Each participant was classified as AM‐I, AMI‐II, or neither. In addition, each participant was classified with regard to whether they met ≥1 of the Bethesda guidelines (yes or no). The specific guideline(s) that the participant met was captured. An individual was categorized as "Bethesda 1" if diagnosed at age \<50 years and "Bethesda 2" if they had an additional Lynch syndrome‐associated cancer diagnoses.[25](#cncr30790-bib-0025){ref-type="ref"}, [26](#cncr30790-bib-0026){ref-type="ref"} Individuals with ≥1 first‐degree relatives with a Lynch syndrome‐associated tumor, with 1 of the cancers being diagnosed before age 50 years, were categorized as "Bethesda 4." Participants with ≥2 first‐degree or second‐degree relatives with Lynch syndrome‐associated tumors, regardless of age at the time of diagnosis, were categorized as "Bethesda 5." The Bethesda guideline 3 pertaining to MSI histology (tumor‐infiltrating lymphocytes, Crohn‐like lymphocytic reaction, mucin/signet ring cell differentiation, medullary growth pattern) was not included in the current study because pathology reports did not uniformly capture these features.

Tumor Tissue Analysis {#cncr30790-sec-0011}
---------------------

For individuals with dMMR tumors and no explanatory germline MMR gene mutation (5 patients) and 1 individual with absent staining for MLH1, MSH6, and PMS2 by IHC, tumor tissue and DNA were sent for tumor sequencing using ColoSeq at the University of Washington. This assay sequences all exons, nonrepeating intronic sequences, and select promoter regions of *AKT1*, *APC*, *AXIN2*, *BMPR1A*, *CDH1*, *CTNNA1*, *EPCAM*, *GALNT12*, *GREM1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *PIK3CA*, *PMS2*, *POLE*, *POLD1*, *PTEN*, *RPS20*, *SMAD4*, *STK11*, and *TP53*. A total of 445 kilobases were sequenced and the average depth of coverage ranged from 320 to \>1000 sequencing reads per base pair (bp). Genomic regions were captured using biotinylated RNA oliognucleotides (SureSelect; Aligent Technologies, Santa Clara, Calif), prepared in paired‐end libraries with an approximately 200‐bp insert size, and sequenced on an Illumina HiSeq2000 instrument (Illumina Inc, San Diego, Calif) with 100‐bp read lengths, in a modification of a procedure described by Pritchard et al.[27](#cncr30790-bib-0027){ref-type="ref"} Large deletions and duplications were detected using methods described by Walsh et al.[28](#cncr30790-bib-0028){ref-type="ref"}

Statistical Analysis {#cncr30790-sec-0012}
--------------------

Descriptive statistics, including means with standard deviations (SDs) and frequency with percentage, were reported for continuous and categorical variables, respectively. Univariate analyses were performed using Student *t* tests and 1‐way analysis of variance for continuous variables, when appropriate. Pearson chi‐square or Fisher exact tests were conducted on categorical outcomes. Univariate multinomial logistic regression was applied to explore the relationship between clinicopathologic characteristics and tumor MMR status among patients in the USC subset (individuals with dMMR tumors, individuals with normal IHC/MSI tumors, and individuals with no testing performed). A Scheffe post hoc test was applied to examine the direction of the differences between groups for continuous risk factors. A macro, CHISQ_MC (SAS Institute Inc, Cary, NC), was implemented to perform an analogous Tukey‐type multiple comparison on a Pearson chi‐square test for categorical variables.[29](#cncr30790-bib-0029){ref-type="ref"} All statistical tests were 2‐tailed, with an α level of .05. All analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc) and STATA statistical software (version 14.2; StataCorp, College Station, Tex).

RESULTS {#cncr30790-sec-0013}
=======

Patient and Tumor Characteristics of the USC Subset Versus the Population‐Based HCCS {#cncr30790-sec-0014}
------------------------------------------------------------------------------------

Among the 265 participants in the USC subset (48.3% of whom were female and 51.7% of whom were male), the mean age at the time of diagnosis of CRC was 53.7 years (SD, 10.3 years), which was significantly younger than those patients in the population‐based HCCS (aged 57.2 ± 12.2 years; *P*\<.01) (Table [1](#cncr30790-tbl-0001){ref-type="table-wrap"}). The majority of the USC participants were foreign born (Mexico in 52.3% and other Latin countries in 28.6%), a rate that was statistically significantly higher than that of the HCCS cohort (45.1% of whom were born in Mexico and 16.3% in another Latin country; *P*\<.01). Greater than 80% of the entire study population was either overweight or obese, and the mean BMI of the subset was 30.5 kg/m^2^ (SD, 6.6 kg/m^2^), but did not differ from the HCCS cohort. However, patients in the USC subset were less likely to have a prior history of colorectal polyps (*P*\<.01) or to have taken hormone replacement therapy (*P*\<.01) compared with the remaining HCCS cohort. Rates of physical activity, selected medications (nonsteroidal anti‐inflammatory drugs and oral contraceptives), alcohol use, tobacco use, and selected comorbidities (diabetes, Crohn disease, ulcerative colitis, and familial adenomatous polyposis) did not differ significantly between the USC subset and the entire cohort.

###### 

Characteristics of the Study Population

  -----------------------------------------------------------------------------------------------------------------------------
  Characteristics                       Subset\       Other HCCS Participants\   *P* [a](#cncr30790-note-0003){ref-type="fn"}
                                        N = 265       N = 847                    
  ------------------------------------- ------------- -------------------------- ----------------------------------------------
  Age at participation (mean ± SD), y   56.0 (10.6)   60.6 (12.3)                \<.01

  Age at diagnosis (mean ± SD), y       53.7 (10.3)   57.2 (12.2)                \<.01

  Sex                                                                            

  Male                                  137 (51.7)    465 (54.9)                 .36

  Female                                128 (48.3)    382 (45.1)                 

  Birth country                                                                  

  United States                         46 (19.1)     318 (38.6)                 \<.01

  Mexico                                126 (52.3)    372 (45.1)                 

  Other                                 69 (28.6)     134 (16.3)                 

  BMI (mean ± SD)                       30.5 ± 6.6    31.0 ± 14.2                .40

  Physical activity                                                              

  No                                    76 (31.7)     230 (28.0)                 .26

  Yes                                   164 (68.3)    593 (72.0)                 

  Alcohol use                                                                    

  \<1 per wk                            111 (45.9)    337 (40.6)                 .14

  ≥1 per wk                             131 (54.1)    493 (59.4)                 

  Tobacco use                                                                    

  Never                                 142 (59.2)    451 (54.6)                 .21

  Ever                                  98 (40.8)     375 (45.4)                 

  Mean pack per y ± SD                  20.5 ± 84.0   14.6 ± 25.5                .51

  NSAID use                                                                      

  Never                                 127 (52.7)    434 (52.0)                 .84

  Ever                                  114 (47.3)    401 (48.0)                 

  Hormone replacement therapy                                                    

  Never                                 109 (90.1)    291 (78.2)                 \<.01

  Ever                                  12 (9.9)      81 (21.8)                  

  Contraceptive use                                                              

  Never                                 46 (38.3)     160 (42.7)                 .40

  Ever                                  74 (61.7)     215 (57.3)                 

  Diabetes                                                                       

  No                                    184 (76.0)    586 (69.9)                 .08

  Yes                                   58 (24.0)     252 (30.1)                 

  Crohn disease                                                                  

  No                                    238 (99.6)    827 (99.3)                 .51

  Yes                                   1 (0.4)       6 (0.7)                    

  Ulcerative colitis                                                             

  No                                    239 (97.6)    797 (95.6)                 .16

  Yes                                   6 (2.4)       37 (4.4)                   

  Familial adenomatous polyposis                                                 

  No                                    234 (98.7)    804 (97.9)                 .59

  Yes                                   3 (1.3)       17 (2.1)                   

  History of polyps                                                              

  No                                    140 (59.3)    338 (41.1)                 \<.01

  Yes                                   96 (40.7)     484 (58.9)                 

  Family history                                                                 

  First‐degree relative with CRC                                                 

  No                                    231 (87.2)    725 (88.3)                 .62

  Yes                                   34 (12.8)     96 (11.7)                  

  Second‐degree relative with CRC                                                

  No                                    250 (94.3)    444 (92.5)                 .34

  Yes                                   15 (5.7)      36 (7.5)                   

  Cancer localization                                                            

  Localized                             46 (31.3)     342 (44.7)                 \<.01

  Regional                              64 (43.5)     366 (47.8)                 

  Metastatic                            37 (25.2)     57 (7.5)                   

  Tumor location                                                                 

  Proximal colon                        69 (27.1)     223 (26.6)                 .28

  Distal colon                          72 (28.2)     279 (33.3)                 

  Rectum                                114 (44.7)    336 (40.1)                 

  Histologic differentiation                                                     .28

  Well                                  12 (9.0)      74 (10.4)                  

  Moderate                              95 (71.4)     539 (76.0)                 

  Poor                                  25 (18.8)     89 (12.6)                  

  Undifferentiated                      1 (0.8)       7 (1.0)                    
  -----------------------------------------------------------------------------------------------------------------------------

Abbreviations: BMI, body mass index; CRC, colorectal cancer; HCCS, Hispanic Colorectal Cancer Study; NSAID, nonsteroidal anti‐inflammatory drug; SD, standard deviation.

*P* values were derived from the Student *t* test for continuous variables and the chi‐square/Fisher exact test for categorical variables.

With respect to family history, 12.8% of participants in the USC subset reported a first‐degree relative, 5.7% reported a second‐degree relative, and 2.3% reported both a first‐degree and second‐degree relative with CRC, which was similar to estimates in the entire cohort.

Overall, 44.7% of patients in the USC subset had rectal cancer, compared with 40.1% in the HCCS cohort (*P =*.28). However, patients in the USC subset were more likely to have metastatic disease at the time of diagnosis (25.2% vs 7.5%; *P*\<.01) compared with patients in the larger cohort.

In the USC subset, 30% of patients (85 patients) had *KRAS* testing performed, and 40.0% (34 patients) had *KRAS‐*mutant cancers. Among patients with localized colon cancer, 38% received fluoropyrimidine‐based adjuvant chemotherapy and 55% of patients with rectal cancer received neoadjuvant chemotherapy and radiotherapy. Overall, approximately 17% of patients participated in therapeutic clinical trials.

Bethesda Guidelines and Amsterdam Criteria {#cncr30790-sec-0015}
------------------------------------------

On initial review of the USC subset, 3.0% met AM‐I criteria and 0.4% met AM‐II criteria. With respect to Bethesda guidelines, 38.5% met at least 1 guideline, with diagnosis at age \<50 years the most commonly fulfilled criterion. No differences were observed by sex or birth location, except for a marginally significant difference noted between the percentage of individuals meeting Bethesda guidelines who were born in the United States (54.3%) versus Mexico (41.3%) and other Latin countries (31.9%) (*P =*.05) (Table [2](#cncr30790-tbl-0002){ref-type="table-wrap"}). Individuals aged \<50 years were more likely to meet AM‐I and AM‐II criteria (*P*\<.01).

###### 

Clinicopathological Characteristics of the Study Population by Age, Sex, and Birth Location

                        Age at Diagnosis   Sex     Birth Location                                                                                        
  --------------------- ------------------ ------- ---------------- ------- ------- ----- ------ ----- ------ ----- ---- ------ ----- ------ ---- ------ -----
  Bethesda guidelines                                                                                                                                    
  No                    0                  0.0     163              89.6    NA      79    57.7   83    64.8   .23   21   45.7   74    58.7   49   68.1   .05
  Yes                   83                 100.0   19               10.4            58    42.3   45    35.2         25   54.3   52    41.3   23   31.9   
  Criteria 1                                                                                                                                             
  No                    0                  0.0     182              100.0   NA      89    65.0   93    72.7   .19   27   58.7   84    66.7   53   73.6   .24
  Yes                   83                 100.0   0                0.0             48    35.0   35    27.3         19   41.3   42    33.3   19   26.4   
  Criteria 2                                                                                                                                             
  No                    80                 96.4    175              96.2    1.00    131   95.6   124   96.9   .59   43   93.5   120   95.2   71   98.6   .34
  Yes                   3                  3.6     7                3.8             6     4.4    4     3.1          3    6.5    6     4.8    1    1.4    
  Criteria 4                                                                                                                                             
  No                    73                 88.0    172              94.5    0.06    127   92.7   118   92.2   .87   42   91.3   116   92.1   66   91.7   .99
  Yes                   10                 12.0    10               5.5             10    7.3    10    7.8          4    8.7    10    7.9    6    8.3    
  Criteria 5                                                                                                                                             
  No                    80                 96.4    178              97.8    0.68    135   98.5   123   96.1   .21   45   97.8   124   98.4   68   94.4   .26
  Yes                   3                  3.6     4                2.2             2     1.5    5     3.9          1    2.2    2     1.6    4    5.6    
  Amsterdam criteria                                                                                                                                     
  None                  76                 91.6    181              98.9    \<.01   132   96.4   124   96.9   .62   44   95.7   122   96.8   69   95.8   .62
  AM I                  7                  8.4     1                0.5             4     2.9    4     3.1          2    4.3    4     3.2    2    2.8    
  AM II                 0                  0.0     1                0.6             1     0.7    0     0.0          0    0.0    0     0.0    1    1.4    

Abbreviation: NA, not applicable.

*P* values were derived from the chi‐square or Fisher exact test.

A total of 161 participants in the USC subset (60.8%) had IHC and/or MSI testing performed, including 72.8% of individuals (75 individuals) who met Bethesda guidelines (103 individuals) (Fig. [1](#cncr30790-fig-0001){ref-type="fig"}). Among those for whom tumor studies were performed, 13.0% (21 patients) had dMMR tumors. Of the individuals with dMMR tumors, greater than one‐third did not meet Bethesda guidelines, and only 1 met Amsterdam criteria. Thirty of the 104 patients who did not have IHC or MSI performed (28.8%) were diagnosed at outside hospitals and later transferred care to USC‐affiliated hospitals. Of these, 3 individuals were diagnosed outside of the United States, and none of the US‐based referring institutions reported ordering MSI or IHC. Two additional individuals did not undergo MSI or IHC testing, but underwent germline genetic testing based on clinical criteria (both met Bethesda guidelines and 1 patient met AM‐II) and were found to carry *MLH1* mutations (patients22 and 23) (Table [3](#cncr30790-tbl-0003){ref-type="table-wrap"}) (Fig. [1](#cncr30790-fig-0001){ref-type="fig"}).

###### 

Somatic and Germline Analysis of Patients With MMR‐Deficient Tumors and/or Lynch Syndrome

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
       Clinical History                            Immunohistochemistry of MMR Proteins   Germline Analysis   Somatic Tumor Sequencing                                                                                                         
  ---- ------------------------------------------- -------------------------------------- ------------------- -------------------------- --------- --------- --------- ---------------- ------------------ --------------------- ------------- ---------------------------------
  1    Transverse colon/60                         No                                     No                  Absent                     Present   Present   Absent    c.2041G\>A       NA                 NA                    NA            NA

  2    Ascending colon/30                          Yes                                    No                  Absent                     Present   Present   Absent    c.1852_1854del   ‐                  ‐                                   NA

  3    Ascending colon/28                          Yes                                    No                  Absent                     Present   Present   Absent    c.393_396del     ‐                  ‐                     ‐             NA

  4    Descending colon/51                         No                                     No                  Absent                     Present   Present   Absent    del exon 14      ‐                  ‐                     ‐             NA

  5    Left‐sided colon/45; renal cell cancer/46   Yes                                    No                  Absent                     Present   Present   Absent    del exons 2‐3    ‐                  NA                    NA            NA

  6    Sigmoid colon/64                            Yes                                    Yes                 Absent                     Present   Present   Absent    c.2634+1G\>T     NA                 NA                    NA            NA

  7    Splenic flexure/51                          No                                     No                  Absent                     Present   Absent    Absent    ‐                ‐                  del exon 6            ‐             *MLH1* c.350C\>T\
                                                                                                                                                                                                                                               *MLH1* c.1975C\>T\
                                                                                                                                                                                                                                               *MSH6* c.2079del\
                                                                                                                                                                                                                                               Biallelic loss of *MSH6* exon 6

  8    Transverse colon/58                         No                                     No                  Present                    Absent    Absent    Present   ‐                c.1705_1706delAG   ‐                     NA            NA

  9    Rectal/41                                   Yes                                    No                  Present                    Absent    Absent    Present   ‐                c.1786_1788del     ‐                     ‐             NA

  10   Ascending colon/41; transverse colon/41     Yes                                    No                  Present                    Absent    Absent    Present   ‐                c.1968C\>G         NA                    NA            NA

  11   Rectum/43                                   Yes                                    No                  Present                    Absent    Absent    Present   ‐                c.1046C\>G         ‐                     ‐             NA

  12   Transverse colon/50                         No                                     No                  Present                    Present   Absent    Present   NA               NA                 c.3255_3256del2ins4   NA            NA

  13   Rectum/40                                   Yes                                    No                  Present                    Present   Present   Absent    NA               NA                 NA                    c.538‐2A\>G   NA

  14   Ascending colon/60                          Yes                                    No                  Absent                     Present   Present   Absent    ‐                ‐                  ‐                     ‐             *MLH1* c.1852_1854del with LOH

  15   Sigmoid colon/50                            Yes                                    No                  Absent                     Present   Present   Absent    ‐                ‐                  ‐                     ‐             No MMR mutations\
                                                                                                                                                                                                                                               *BRAF* ^V600E^ negative\
                                                                                                                                                                                                                                               MSI stable

  16   Ascending colon/52                          No                                     No                  Absent                     Present   Present   Absent    ‐                ‐                  ‐                     ‐             *MLH1* c.--42C\>T\
                                                                                                                                                                                                                                               with LOH

  17   Ascending colon/48                          Yes                                    No                  Present                    Absent    Absent    Present   ‐                ‐                  ‐                     ‐             *MSH2* c.1076+1G\>T\
                                                                                                                                                                                                                                               *MSH2* c.14del\
                                                                                                                                                                                                                                               *MSH6* c.3261dup

  18   Ascending colon/47                          Yes                                    No                  Present                    Absent    Absent    Present   NA               ‐                  ‐                     NA            *MSH2* c.1045C\>G\
                                                                                                                                                                                                                                               with LOH

  19   Ascending colon/58                          No                                     No                  Absent                     Present   Present   Absent    NA               NA                 NA                    NA            *MLH1* c.1400del\
                                                                                                                                                                                                                                               with LOH

  20   Sigmoid colon/60                            No                                     No                  Absent                     Present   Present   Absent    NA               NA                 NA                    NA            NA

  21   Ascending colon/85                          No                                     No                  Absent                     Present   Present   Absent    NA               NA                 NA                    NA            NA

  22   Transverse colon/45                         Yes                                    No                  NA                         NA        NA        NA        c.1989 +5G\>T    ‐                  ‐                     ‐             NA

  23   Appendix/40                                 Yes                                    Yes                 NA                         NA        NA        NA        c.1852_1854del   ‐                  ‐                     ‐             NA
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ---, the gene was tested and no mutations were identified; del, deletion; LOH, loss of heterozygosity; *MLH1*, MutL homolog 1; MMR, mismatch repair; *MSH2*, MutS homolog 2; *MSH6*, MutS homolog 6; MSI, microsatellite instability; NA, testing was not performed; *PSM2*, PMS1 homolog 2, mismatch repair system component.

![Tumor immunohistochemistry (IHC) of mismatch repair (MMR) proteins and germline testing for hereditary colorectal cancer syndromes. *APC* indicates adenomatous polyposis coli; *MLH1*, MutL homolog 1; *MSH2*, MutS homolog 2; *MSH6*, MutS homolog 6; MSI, microsatellite instability; *PSM2*, PMS1 homolog 2, mismatch repair system component.](CNCR-123-3732-g001){#cncr30790-fig-0001}

Germline Genetic Testing and Somatic Tumor Studies {#cncr30790-sec-0016}
--------------------------------------------------

Of the 265 participants in the USC subset, 29.8% (79 patients) underwent germline genetic testing including 18 of the 21 individuals with dMMR tumors (Fig. [1](#cncr30790-fig-0001){ref-type="fig"}). The majority of the analyses (64 patients; 81.0%) were performed using a 25‐gene panel and the remaining 15 individuals had genetic tests ordered for ≥1 MMR or polyposis genes (Table [3](#cncr30790-tbl-0003){ref-type="table-wrap"}). Overall, 19.0% of the individuals (15 patients) who underwent genetic testing were confirmed to have Lynch syndrome, representing 5.7% of the USC subset. Six individuals (2.3%) had a colonic polyposis phenotype, and 3 underwent germline testing. Two of these patients were found to have an *APC* mutation and the third was revealed to be a biallelic *MUTYH* mutation carrier (see Supporting Information Table 1). Only 1 monoallellic *MUTYH* mutation carrier was identified in the tested group. No other pathogenic mutations were identified; however, 37 variants of uncertain clinical significance were identified among 27 individuals (see Supporting Information Table 2).

Among the 21 patients with dMMR tumors, 85.7% (18 patients) underwent clinical germline testing, with a pathogenic MMR mutation identified in 13 individuals (72.2%) (Fig. [1](#cncr30790-fig-0001){ref-type="fig"}). Among the 9 individuals with dMMR tumors who either had uninformative germline genetic testing (5 patients) or who did not undergo clinical genetic testing (3 patients), 6 had tumor tissue available for ColoSeq analysis. Five of the 6 patients were found to have somatic mutations and/or evidence of loss of heterozygosity (LOH) that explained the dMMR nature of their tumors. In one individual (patient 15) (Table [3](#cncr30790-tbl-0003){ref-type="table-wrap"}), no somatic or germline mutation was identified to explain the loss of expression of MLH1 and PMS2. In addition, the tumor from patient 7 demonstrated loss of MLH1, MSH6, and PMS2 staining and germline testing confirmed a deletion of exon 6 in *MSH6*. This deletion also was identified with somatic tumor sequencing along with 2 *MLH1* mutations, most likely explaining the lack of MLH1 and PMS2 staining.

Among individuals with confirmed Lynch syndrome (15 patients), the majority of cancers occurred in the colon (80%) versus the rectum (20%) and among those occurring in the colon, 67% were located in the proximal colon. In addition, although the majority of patients with Lynch syndrome (10 patients; 66.7%) did meet Bethesda guidelines, only 2 (13.3%) met AM‐1 or AM‐II criteria. Overall, 5 of the patients with Lynch syndrome in the cohort (33.3%) would not have been identified by Bethesda guidelines or Amsterdam criteria alone.

Only 5.5% of all patients (15 patients) had *BRAF* testing performed, with 13.3% of the patients (2 patients) found to harbor tumors with *BRAF* ^V600E^ mutations. However, these 2 individuals were not part of the group with dMMR tumors; 1 had an MMR‐proficient tumor according to IHC results and the other individual had neither MSI nor IHC performed.

Clinicopathologic Characteristics Stratified by Tumor dMMR Status {#cncr30790-sec-0017}
-----------------------------------------------------------------

The mean age at the time of CRC diagnosis of those with dMMR tumors was 50.4 years (SD, 12.4 years), which was similar to that of individuals with normal IHC/MSI MMR‐proficient tumors (51.4 ± 9.5 years; *P =*.91) (Table [4](#cncr30790-tbl-0004){ref-type="table-wrap"}). Individuals diagnosed at older ages were significantly less likely to have had IHC or MSI performed, which is a reflection of clinical practice (57.5 ± 9.8 years; *P*\<.01). The prevalence of dMMR tumors was higher in women compared with men, but this did not reach statistical significance after adjusting for multiple comparisons (61.9% vs 47.1%; *P =*.42). Individuals with a first‐degree (23.8% vs 10%) or second‐degree (9.5% vs 7.1%) family member diagnosed with CRC also were more likely to have dMMR tumors compared with MMR‐proficient tumors, but this finding did not reach statistical significance. However, dMMR tumors were statistically significantly more likely to be located in the proximal colon compared with the distal colon/rectum (*P*\<.01).

###### 

Clinicopathologic Characteristics Stratified by Tumor Mismatch Repair Status

                                                Individuals With dMMR Tumors   Individuals With Proficient MMR Tumors   MSI/IHC Testing Not Performed                   
  --------------------------------------------- ------------------------------ ---------------------------------------- ------------------------------- ------- ------- -------
  Mean age at the time of diagnosis (± SD), y   50.4 ± 12.4                    51.4 ± 9.5                               57.5 ± 9.8                      .91     \<.01   \<.01
  Sex                                                                                                                                                                   
  Male                                          8 (38.1)                       74 (52.9)                                55 (52.9)                       .42     .37     .43
  Female                                        13 (61.9)                      66 (47.1)                                49 (47.1)                                       
  Birth country                                                                                                                                                         
  United States                                 3 (15.0)                       22 (17.0)                                21 (22.1)                       .92     .13     .82
  Mexico                                        10 (50.0)                      70 (54.3)                                46 (48.4)                                       
  Other                                         7 (35.0)                       37 (28.7)                                28 (29.5)                                       
  Cancer localization                                                                                                                                                   
  Localized                                     6 (60.0)                       17 (34.0)                                10 (29.4)                       .43     .88     .58
  Regional                                      3 (30.0)                       22 (44.0)                                17 (50.0)                                       
  Metastatic                                    1 (10.0)                       11 (22.0)                                7 (20.6)                                        
  BMI                                                                                                                                                                   
  Mean ± SD, kg/m^2^                            31.4 (9.0)                     30.4 (6.6)                               30.3 (6.1)                      .84     1.00    .82
  Diabetes                                                                                                                                                              
  No                                            15 (75.0)                      103 (80.5)                               66 (70.2)                       .99     .70     .21
  Yes                                           5 (25.0)                       25 (19.5)                                28 (29.8)                                       
  Alcohol use                                                                                                                                                           
  \<1 per wk                                    12 (60.0)                      57 (44.5)                                42 (44.7)                       .30     .95     .42
  ≥1 per wk                                     8 (40.0)                       71 (55.5)                                52 (55.3)                                       
  Smoking                                                                                                                                                               
  Never                                         13 (65.0)                      76 (59.8)                                53 (57.0)                       .95     .95     .78
  Ever                                          7 (35.0)                       51 (40.2)                                40 (43.0)                                       
  Mean pack‐y ± SD                              6.51 ± 4.1                     11.24 ± 17.9                             34.43 ± 128.8                   .99     .45     .41
  NSAID Use                                                                                                                                                             
  Never                                         12 (60.0)                      69 (54.3)                                46 (48.9)                       .96     .68     .58
  Ever                                          8 (40.0)                       58 (45.7)                                48 (51.1)                                       
  Postmenopausal hormones                                                                                                                                               
  Never                                         12 (100.0)                     56 (88.9)                                41 (87.2)                       .56     .83     .44
  Ever                                          0 (0.0)                        7 (11.1)                                 6 (12.8)                                        
  Oral contraceptive use                                                                                                                                                
  Never                                         6 (50.0)                       16 (25.8)                                25 (53.2)                       .70     .47     .01
  Ever                                          6 (50.0)                       46 (74.2)                                22 (46.8)                                       
  Family history                                                                                                                                                        
  First‐degree relative with CRC                                                                                                                                        
  No                                            16 (76.2)                      126 (90.0)                               89 (85.6)                       .17     .58     .16
  Yes                                           5 (23.8)                       14 (10.0)                                15 (14.4)                                       
  Second‐degree relative with CRC                                                                                                                                       
  No                                            19 (90.5)                      130 (92.9)                               101 (97.1)                      .91     .23     .17
  Yes                                           2 (9.5)                        10 (7.1)                                 3 (2.9)                                         
  Primary tumor location                                                                                                                                                
  Proximal colon                                13 (61.9)                      33 (24.4)                                23 (23.2)                       \<.01   .79     \<.01
  Distal colon                                  5 (23.8)                       42 (31.1)                                25 (25.3)                                       
  Rectum                                        3 (14.3)                       60 (44.5)                                51 (51.5)                                       

Abbreviations: BMI, body mass index; CRC, colorectal cancer; dMMR, mismatch repair‐deficient; IHC, immunohistochemistry; MSI, microsatellite instability; NSAID, nonsteroidal anti‐inflammatory drug; SD, standard deviation.

*P* values were derived from analysis of variance for continuous variables with Scheffe adjustment for multiple comparisons and from the chi‐square/Fisher exact test for categorical variables with Tukey adjustment for multiple comparisons.

^b^ *P* values were derived from analysis of variance for continuous variables and the chi‐square/Fisher exact test for categorical variables.

DISCUSSION {#cncr30790-sec-0018}
==========

To our knowledge, the current study represents one of the largest cohorts of Latino patients diagnosed with CRC with reported germline genetic and somatic tumor testing in the United States performed to date. The findings suggest that the rate of dMMR tumors in Latino individuals is 13.0%, which is similar to previous estimates.[20](#cncr30790-bib-0020){ref-type="ref"}, [30](#cncr30790-bib-0030){ref-type="ref"} In contrast with other studies, we were able to perform more in‐depth molecular analysis to confirm that the majority of the dMMR tumors (61.9%) were indeed attributable to germline MMR gene mutations. In the current study sample, we also observed a younger age at the time of onset, a higher percentage of rectal cancers, and advanced disease in Latino patients, which is consistent with observations in other studies.[6](#cncr30790-bib-0006){ref-type="ref"}, [8](#cncr30790-bib-0008){ref-type="ref"}

The incidence of dMMR tumors in Latino patients has been examined in various Latino populations in the United States as well as in South America and the Caribbean.[31](#cncr30790-bib-0031){ref-type="ref"}, [32](#cncr30790-bib-0032){ref-type="ref"}, [33](#cncr30790-bib-0033){ref-type="ref"}, [34](#cncr30790-bib-0034){ref-type="ref"}, [35](#cncr30790-bib-0035){ref-type="ref"} In the United States, 2 small studies reported MSI in 16.9%[36](#cncr30790-bib-0036){ref-type="ref"} and 19.0%[37](#cncr30790-bib-0037){ref-type="ref"} of Latinos, respectively. In Puerto Rico, a larger retrospective study investigated an unselected group of Latino patients with CRC, among whom IHC staining of only 2 MMR proteins (MLH1 and MSH2) was performed.[22](#cncr30790-bib-0022){ref-type="ref"} Among 164 individuals, only 8 demonstrated any loss of protein expression by IHC (7 patients with absent MSH2 and 1 patient with absent MLH1) and were presumed to have Lynch syndrome. Overall, those studies concluded that the rate of dMMR tumors (4.3%) was lower than that reported in other populations, with the majority of cases attributable to Lynch syndrome. A hospital‐based study in Texas[30](#cncr30790-bib-0030){ref-type="ref"} conducted a retrospective review of tumor registry data in Latino patients and performed MSI and IHC on all 4 MMR proteins (MLH1, MSH2, MSH6, and PMS2). In the 111 patients with CRC they studied, 9.8% had tumors demonstrating MSI and 14.6% had abnormal IHC expression. The authors concluded that the rate of dMMR tumors was similar to that of other populations, and that a greater percentage of tumors were attributable to Lynch syndrome, although these authors also were unable to perform genetic testing for confirmation. A third hospital‐based study of 103 surgically resected CRC specimens from Latino patients in Miami found that 12.6% of tumors demonstrated abnormal IHC, but again the authors were unable to confirm cases of Lynch syndrome with germline testing.[21](#cncr30790-bib-0021){ref-type="ref"} Lastly, a meta‐analysis combining data in 3 of these studies reported that 12% of tumors (range, 7%‐16%) diagnosed among Latino patients were dMMR.[20](#cncr30790-bib-0020){ref-type="ref"} The results of the current study similarly suggest that the rate of dMMR tumors in Latino individuals is approximately 13%.

Berera et al compared rates among NHW, Latino, and African American patients and observed no differences in the rate of dMMR tumors by ethnicity/race[21](#cncr30790-bib-0021){ref-type="ref"}; similar results also were observed in a larger meta‐analysis.[20](#cncr30790-bib-0020){ref-type="ref"} However, several studies have hypothesized that Lynch syndrome may explain a high percentage of Latino patients with CRC who have dMMR tumors. After conducting additional germline and somatic tumor testing, which had been lacking in the previously reported studies, we observed that 13 of 21 patients (61.9%) had a germline mutation in a MMR gene, confirming that these individuals have Lynch syndrome. The current study findings, although suggestive, should be interpreted with caution because the entire cohort did not have IHC or MSI performed. Furthermore, the apparent lower prevalence of sporadic MSI CRC among Latino individuals is not entirely understood and may be due to chance. Some have hypothesized that this finding may reflect differences in environmental and lifestyle factors between Latino individuals and other populations. For example, MSI‐H CRC has been associated with tobacco use,[36](#cncr30790-bib-0036){ref-type="ref"}, [38](#cncr30790-bib-0038){ref-type="ref"} which is less prevalent in Latinos compared with other populations,[39](#cncr30790-bib-0039){ref-type="ref"} and a high BMI, which is more common in Latino individuals, is associated with microsatellite stable CRC tumors.[40](#cncr30790-bib-0040){ref-type="ref"} Further studies are needed to investigate these hypotheses.

Furthermore, recent studies investigating the underlying etiology of dMMR[41](#cncr30790-bib-0041){ref-type="ref"}, [42](#cncr30790-bib-0042){ref-type="ref"}, [43](#cncr30790-bib-0043){ref-type="ref"} have demonstrated that 52% to 69% of unexplained dMMR cases are attributable to multiple somatic MMR mutations or LOH. This is clinically significant because individuals with unexplained dMMR tumors, especially loss of MSH2 and MSH6, often are managed as having Lynch syndrome, despite the lack of a detectable germline mutation. Among individuals in the current study with dMMR tumors, there were 5 individuals in whom no germline mutations were identified as well as 1 individual who did not undergo germline genetic testing who had tumor tissue available for further studies. Sequencing was performed and 5 of the 6 patients (83.3%) were found to have multiple somatic MMR mutations and/or evidence of LOH, which potentially explains the dMMR. The findings of the current study add to the growing body of literature demonstrating the contribution of double somatic mutations to dMMR CRC tumors.

Although to our knowledge only a few studies have been conducted to date, the mutational spectrum of Lynch syndrome may vary by Latino subgroup. Latinos are the result of \>500 years of admixture of European, Amerindian, and African individuals, with varying degrees across Latin America.[44](#cncr30790-bib-0044){ref-type="ref"} Moreover, US Latinos include recent immigrants who make similar lifestyle and dietary choices as those in their countries of origin, as well as second‐generation or higher immigrants born in the United States who are partially or fully assimilated to the US lifestyle. Both genetic ancestry and lifestyle factors may be associated with tumor characteristics and help to explain differences in the mutation spectrum as observed in different studies. For example, Berera et al observed that MSH2‐deficient tumors were overrepresented in Latino individuals from Miami[21](#cncr30790-bib-0021){ref-type="ref"} (who are disproportionately of Cuban origin). Similarly, a case series study among Caribbean Hispanics from Puerto Rico and the Dominican Republic demonstrated that the mutation spectrum was largely composed of *MSH2* (66.7%) mutations followed by *MLH1* (25%) and *MSH6* (8.3%) mutations.[35](#cncr30790-bib-0035){ref-type="ref"} In comparison, the current California‐based study identified *MLH1* mutations in 53.3% of individuals, *MSH2* mutations in 26.7% of individuals, *MSH6* mutations in 13.3% of individuals, and *PMS2* mutations in 6.7% of individuals. Latinos from California are largely of Mexican origin, with a higher percentage of Amerindian ancestry compared with those Latino individuals from Florida or the Caribbean, who are more likely to have a higher percentage of African ancestry.[45](#cncr30790-bib-0045){ref-type="ref"} We were unable to fully investigate differences in the mutational spectrum by ancestry and further studies are needed on the subject.

It is interesting to note that approximately one‐half of the current study cohort had rectal cancer, which is higher than that reported in the general population (approximately one‐third of patients with CRC). This may reflect the disproportionately younger age of the patients in the current study. Rectal cancer has been steadily rising in incidence among individuals aged \<50 years,[46](#cncr30790-bib-0046){ref-type="ref"}, [47](#cncr30790-bib-0047){ref-type="ref"}, [48](#cncr30790-bib-0048){ref-type="ref"} and younger patients are more likely to present with poorly differentiated and late‐stage cancers. Previous studies also have suggested that Latino individuals (in particular Mexicans)[8](#cncr30790-bib-0008){ref-type="ref"} have high rates of rectal cancer,[9](#cncr30790-bib-0009){ref-type="ref"}, [47](#cncr30790-bib-0047){ref-type="ref"} although the reasons remain unclear.

Certain limitations of the current study should be acknowledged. The study population herein was recruited from Los Angeles, an area where the majority of Latino individuals are of Mexican origin compared with other Latin American countries,[45](#cncr30790-bib-0045){ref-type="ref"} which may limit the generalizability of the current study findings to all Latino groups. Furthermore, we were unable to analyze the data by ancestry or nativity due to the limited sample size. Another limitation is that approximately 40% of the current study cohort did not have MSI and/or IHC performed. The subgroup without tumor studies was similar to the group with MMR‐proficient tumors with regard to the lower frequency of proximal tumors and the lack of affected relatives. These individuals also were older (mean age, 57.5 years). Therefore, the untested cohort is less likely to have dMMR tumors and if such tumors were present, the etiology is more likely to be sporadic or somatic rather than germline in nature. This limitation could lead to an underrepresentation of sporadic dMMR tumors over the cohort and could explain, in part, the large percentage of dMMR tumors explained by Lynch syndrome.

The current study had many strengths. Among them, all 4 MMR proteins were studied, which is in contrast to previous reports, and nearly 30% of the cohort in the current study underwent germline genetic testing, including the majority of individuals with dMMR tumor studies (18 of 21 individuals; 85.7%), thereby allowing for a more comprehensive assessment of the underlying mechanism behind the dMMR tumors. In addition, somatic tumor testing provided greater insight into the etiology of the unexplained dMMR tumors. Cases were identified using a population‐based cancer registry, which contributes to the generalizability of the current study findings. Although our characterization was restricted to 2 specific centers, we were able to compare the subset of the data used in the current study from USC‐affiliated hospitals with the characteristics of a population‐based sample in California, which provides additional information regarding the generalizability of the findings presented herein.

The results of the current study suggest that Latino individuals have similar rates of dMMR tumors compared with NHW individuals. We confirmed that the majority of these cancers are attributable to Lynch syndrome. Further research is needed to understand whether there is a lower percentage of tumors with high MSI in the Latino population.
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